Every 10-Q that Tarsus Pharmaceuticals, Inc. (TARS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
Tarsus Pharmaceuticals, Inc. reported higher revenue and a reduced net loss for the quarter ended June 30, 2026. Total revenues were $173.9 million versus $102.7 million a year earlier, driven entirely by XDEMVY product sales. Net loss for the quarter narrowed to $18.6 million, or $0.43 per share, compared with $20.3 million, or $0.48 per share.
For the first six months of 2026, revenue reached $336.0 million, including $319.3 million of product sales and $16.7 million of license and collaboration revenue. Operating expenses grew as Tarsus expanded R&D and commercial operations, but loss from operations improved to $26.0 million from $48.5 million.
Tarsus generated $36.6 million of net cash from operating activities in the first half of 2026, compared with $50.0 million of cash used a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled over $451 million, and management estimates existing capital resources will cover at least 12 months of projected needs. The company remains heavily dependent on XDEMVY for Demodex blepharitis and continues to invest in pipeline candidates TP-04 and TP-05 while highlighting significant commercialization, market, supply, and clinical development risks.
Tarsus Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenue reached $162.1 million, driven by $145.4 million in XDEMVY product sales and $16.7 million of license and collaboration revenue.
Operating expenses rose to $168.2 million, mainly from higher selling, general and administrative and R&D spending. Net loss narrowed to $7.0 million, or $0.16 per share, compared with a $25.1 million loss a year earlier. Cash, cash equivalents and marketable securities totaled over $388 million, and management believes existing capital will fund operations for at least 12 months, though additional financing may still be needed as the company scales commercialization and advances its pipeline.
Tarsus Pharmaceuticals reported Q3 2025 results showing rapid commercial growth of XDEMVY and continued investment in commercialization. Product sales, net were $118.7 million, up from $48.1 million a year ago. The company posted a net loss of $12.6 million, with operating expenses led by selling, general and administrative of $108.6 million, research and development of $16.3 million, and cost of sales of $8.3 million.
For the nine months, product sales, net totaled $299.7 million and the net loss was $58.0 million. Liquidity strengthened: cash and cash equivalents were $112.7 million and marketable securities were $289.1 million as of September 30, 2025. Stockholders’ equity reached $335.1 million, with long‑term debt of $72.3 million. The company completed a March 2025 follow‑on offering for approximately $134.8 million in net proceeds to support operations. Shares outstanding were 42,449,105 as of October 29, 2025.